DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that, following the presentation of full the data set from the NEO3-09 clinical trial of Lymphoseek at the American Society of Clinical Oncology (ASCO) Meeting yesterday in Chicago, two of the principal investigators in the trial participated with Company representatives in an event for analysts and institutional investors last evening following the poster session. Dr. Anne Wallace of the Moores Cancer Center, University of California San Diego, and Dr. Vernon Sondak of the H. Lee Moffitt Cancer Center presented their experience in the trials to the select group of analysts and institutional investors. Copies of the slides presented by Dr. Wallace, Dr. Sondak and the Company at the event, along with audio recordings of their presentations, are available to investors and interested parties at the Company’s website at www.neoprobe.com/ASCO2011.asp.
